Cargando…

Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy

Natural killer (NK) cells are innate immune cells that can be activated rapidly to target abnormal and virus-infected cells without prior sensitization. With significant advancements in cell biology technologies, many NK cell lines have been established. Among these cell lines, NK-92 cells are not o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jianguang, Zheng, Huifang, Diao, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358726/ https://www.ncbi.nlm.nih.gov/pubmed/30646574 http://dx.doi.org/10.3390/ijms20020317

Ejemplares similares

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
por: Klingemann, Hans, et al.
Publicado: (2016)

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
por: Mehta, Rohtesh S., et al.
Publicado: (2018)

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
por: Yilmaz, Ahmet, et al.
Publicado: (2020)

Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
por: Wang, Yan, et al.
Publicado: (2023)

Cordycepin Sensitizes Cholangiocarcinoma Cells to Be Killed by Natural Killer-92 (NK-92) Cells
por: Panwong, Suthida, et al.
Publicado: (2021)

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
por: Gong, Ying, et al.
Publicado: (2021)

Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV
por: Liu, Dongfang, et al.
Publicado: (2017)

Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review)
por: Peng, Xiaobo, et al.
Publicado: (2021)

Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment
por: Bahmanyar, Maryam, et al.
Publicado: (2022)

CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
por: Kim, Hyori, et al.
Publicado: (2023)

Erratum to: Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV
por: Liu, Dongfang, et al.
Publicado: (2017)

Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer
por: Shang, Yufeng, et al.
Publicado: (2019)

Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors
por: Kim, Nayoung, et al.
Publicado: (2021)

Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects
por: Elahi, Reza, et al.
Publicado: (2021)

Adapter Chimeric Antigen Receptor (AdCAR)-Engineered NK-92 Cells for the Multiplex Targeting of Bone Metastases
por: Grote, Stefan, et al.
Publicado: (2021)

Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells
por: Shiozawa, Masayuki, et al.
Publicado: (2018)

Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity
por: Hermanson, David L., et al.
Publicado: (2015)

Chimeric antigen receptor engineered natural killer cells for cancer therapy
por: Zhang, Yalan, et al.
Publicado: (2023)

Natural Killer Cell Line NK-92-Mediated Damage of Medically Important Fungi
por: Schmidt, Stanislaw, et al.
Publicado: (2021)

Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma
por: Dai, Kai, et al.
Publicado: (2021)

Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells
por: Reighard, Seth D., et al.
Publicado: (2020)

Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment
por: Oberschmidt, Olaf, et al.
Publicado: (2017)

Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
por: Wang, Xiao, et al.
Publicado: (2022)

Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer
por: Obajdin, J., et al.
Publicado: (2020)

Nanoparticle Enhancement of Natural Killer (NK) Cell-Based Immunotherapy
por: Murugan, Dhanashree, et al.
Publicado: (2022)

Selection and expansion of natural killer cells for NK cell-based immunotherapy
por: Becker, Petra S. A., et al.
Publicado: (2016)

Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting
por: Grote, Stefan, et al.
Publicado: (2020)

Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123
por: Morgan, Michael A., et al.
Publicado: (2021)

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
por: Poels, Renée, et al.
Publicado: (2021)

Na(+)/H(+)-exchanger 1 Enhances Antitumor Activity of Engineered NK-92 Natural Killer Cells
por: Gong, Yao-Yu, et al.
Publicado: (2022)

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
por: Lee, Maxwell Y, et al.
Publicado: (2021)

Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy
por: Islam, Rasa, et al.
Publicado: (2021)

Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy
por: Sun, Cheng, et al.
Publicado: (2015)

A bibliometric and scientific knowledge-map study of the chimeric antigen receptor (CAR) natural killer (NK) cell-related research from 2010 to 2022
por: Zhang, Juan, et al.
Publicado: (2022)

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
por: Zhang, Congcong, et al.
Publicado: (2017)

Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor
por: Gossel, Leonie D. H., et al.
Publicado: (2021)

Purinergic targeting enhances immunotherapy of CD73(+) solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells
por: Wang, Jiao, et al.
Publicado: (2018)

Enhanced Cytotoxicity of Natural Killer Cells following the Acquisition of Chimeric Antigen Receptors through Trogocytosis
por: Cho, Fu-Nan, et al.
Publicado: (2014)

Proliferation of Highly Cytotoxic Human Natural Killer Cells by OX40L Armed NK-92 With Secretory Neoleukin-2/15 for Cancer Immunotherapy
por: Guo, Meng, et al.
Publicado: (2021)

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells
por: Robbins, Yvette, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_clhud5q6hqh658a9oi7b2p3hra